DARZALEX® Clinical Studies:

DARZALEX® in combination with Revlimid® 
(lenalidomide) + dexamethasone

DARZALEX® was studied in combination with Revlimid® and dexamethasone (Rd) vs Rd alone in 569 people who had received at least one prior medicine to treat their multiple myeloma.

The main goal of the study was to measure the length of time people lived without their multiple myeloma getting worse or passing away from any cause. Another goal was to measure overall response rate, which is the percentage of people who responded to treatment.

Clinical trial results: DARZALEX® + Rd vs Rd alone

DARZALEX® in combination with Rd increased the time people lived without their multiple myeloma getting worse or passing away from any cause.

  • 63% less risk of disease progression or passing away with DARZALEX® in combination with Rd vs Rd alone

At a median follow-up of 13.5 months, 19% of patients treated with D+Rd had disease progression or passed away vs 41% of patients treated with Rd alone.

More people responded to DARZALEX® in combination with Rd vs Rd alone

9 out of 10 people
responded to DARZALEX® + Revlimid® + dexamethasone vs 7 out of 10 people with Revlimid® + dexamethasone